A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial (Q46603388)

23 December 2017

title

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial (English)

1 reference

23 December 2017

main subject

phase I clinical trial

0 references

1 reference

2

Ursula A Matulonis

1 reference

23 December 2017

author name string

Anna Berkenblit

1

1 reference

23 December 2017

Joan F Kroener

3

1 reference

23 December 2017

Bruce J Dezube

4

1 reference

23 December 2017

Gil N Lam

5

1 reference

23 December 2017

Luceli C Cuasay

6

1 reference

23 December 2017

Nils Brünner

7

1 reference

23 December 2017

Terence R Jones

8

1 reference

23 December 2017

Michael H Silverman

9

1 reference

23 December 2017

Michael A Gold

10

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

23 December 2017

published in

Gynecologic Oncology

1 reference

23 December 2017

volume

99

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

50-57

1 reference

23 December 2017

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

The urokinase plasminogen activator system: role in malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Matrix metalloproteinases: biologic activity and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.023

10.1016/J.YGYNO.2005.05.023

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

16023182

1 reference

23 December 2017